Mocotac (Acetylcysteine)

Acetylcysteine, the active ingredient in Mocotac, is a mucolytic presented as an oral formulation for oral use. It reduces the viscosity of thick respiratory secretions by breaking disulfide bonds in mucus glycoproteins, thereby facilitating expectoration and improving airway clearance in patients with acute bronchitis, chronic obstructive pulmonary disease, cystic fibrosis and other conditions characterized by viscous sputum.

GNH USA supplies Mocotac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export.

Mocotac (acetylcysteine) acts on respiratory mucus to improve clearance in several pulmonary conditions.

- Acute bronchitis: reduces sputum thickness, eases coughing and promotes clearance of mucus in the airways. - Chronic obstructive pulmonary disease (COPD): thins viscous secretions, facilitating expectoration and potentially improving airflow limitation. - Cystic fibrosis: breaks disulfide bonds in thick mucus, supporting airway hygiene and reducing infection risk. - Chronic bronchitis: lowers mucus viscosity, making it easier to expectorate and improving respiratory comfort.

Acetylcysteine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Abdominal discomfort - Headache - Rash

Serious or Rare Side Effects: - Anaphylactic reaction - Severe skin eruptions such as Stevens‑Johnson syndrome - Bronchospasm - Hepatic dysfunction - Neutropenia - Renal impairment

When using Mocotac, several precautionary measures should be observed to ensure safety. - Assess renal function: adjust use in patients with severe renal impairment. - Monitor hepatic enzymes: watch for signs of liver dysfunction during therapy. - Avoid in known hypersensitivity: discontinue immediately if allergic reaction occurs. - Use caution in asthma: may provoke bronchospasm, especially with inhaled formulations. - Pregnancy and lactation: consult a healthcare professional before use. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Acetylcysteine can interact with other medicines, influencing their efficacy or safety profile.

Major Interactions (Avoid): - Nitroglycerin: concurrent use may cause marked hypotension. - Carbapenem antibiotics (e.g., imipenem): increased risk of rash and allergic reactions. - Chemotherapeutic agents that rely on glutathione: may alter drug metabolism. - Warfarin: potential enhancement of anticoagulant effect, requiring close monitoring.

Moderate Interactions (Monitor Closely): - Bronchodilators (e.g., β2‑agonists): may enhance bronchodilatory response. - ACE inhibitors: monitor blood pressure for additive hypotensive effect. - Diuretics: observe electrolyte balance, especially potassium levels.